Herpes Virus

Two doses of the recombinant herpes zoster vaccine Shingrix induced “strong and persistent” immune responses in older adults, irrespective of whether they previously received the live-attenuated herpes zoster vaccine, Zostavax, according to results from a study published in The Journal of Infectious Diseases.

An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.

Herpes zoster (HZ) continues to be a relevant public health issue because of its prevalence and potential complications. It is estimated that one out of three people in the United States will develop HZ in their lifetime. Varicella zoster virus, the cause of HZ, is one of eight herpes viruses that infect humans.